CellCept (Mycophenolate Mofetil)
( DrugBank: Mycophenolate mofetil, Mycophenolate / KEGG DRUG: Mycophenolate mofetil, Mycophenolic acid )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 42 | Polyarteritis nodosa | 5 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 43 | Microscopic polyangiitis | 1 |
42. Polyarteritis nodosa
Clinical trials : 15 / Drugs : 26 - (DrugBank : 16) / Drug target genes : 26 - Drug target pathways : 105
Showing 1 to 5 of 5 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2013-004668-71-ES (EUCTR) | 13/10/201620161013 | 05/08/201620160805 | A study of treatment for polyarteritis nodosa in children | An Open Label Randomised Controlled Trial of Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission of Childhood Polyarteritis Nodosa - MYPAN An Open Label Randomised Controlled Trial of Mycophenolate Mofetil Versus Cyclophosphamide for the I ... | Childhood systemic polyarteritis nodosa (PAN) MedDRA version: 19.0;Level: LLT;Classification code 10036026;Term: Polyarteritis nodosa of childhood;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Childhood systemic polyarteritis nodosa (PAN) MedDRA version: 19.0;Level: LLT;Classification code 10 ... | Trade Name: CellCept Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: CellCept Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: CellCept (Mycophenolate Mofetil) Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: Cyclophosphamide Product Name: Cyclophosphamide INN or Proposed INN: CYCLOPHOSPHAMIDE Trade Name: CellCept Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate ... | University College London | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 3 | Portugal;Slovenia;Greece;Spain;Turkey;United Kingdom;Italy;Czech Republic;Belgium;Poland;Croatia;Germany;Netherlands;Sweden Portugal;Slovenia;Greece;Spain;Turkey;United Kingdom;Italy;Czech Republic;Belgium;Poland;Croatia;Ger ... | ||
| 2 | EUCTR2013-004668-71-IT (EUCTR) | 01/08/201620160801 | 14/07/201520150714 | An Open Label Randomised Controlled Trial of Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission of Childhood Polyarteritis Nodosa - MYPAN An Open Label Randomised Controlled Trial of Mycophenolate Mofetil Versus Cyclophosphamide for the I ... | An Open Label Randomised Controlled Trial of Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission of Childhood Polyarteritis Nodosa - MYPAN An Open Label Randomised Controlled Trial of Mycophenolate Mofetil Versus Cyclophosphamide for the I ... | Childhood systemic polyarteritis nodosa (PAN) MedDRA version: 19.0;Level: LLT;Classification code 10036026;Term: Polyarteritis nodosa of childhood;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Childhood systemic polyarteritis nodosa (PAN) MedDRA version: 19.0;Level: LLT;Classification code 10 ... | Trade Name: CellCept Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: CellCept Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: CellCept (Mycophenolate Mofetil) Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: Cyclophosphamide Product Name: Cyclophosphamide Trade Name: CellCept Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate ... | University College London | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 3 | Portugal;Slovenia;Greece;Spain;Turkey;United Kingdom;Italy;Czech Republic;Belgium;Poland;Croatia;Germany;Netherlands;Sweden Portugal;Slovenia;Greece;Spain;Turkey;United Kingdom;Italy;Czech Republic;Belgium;Poland;Croatia;Ger ... | ||
| 3 | EUCTR2013-004668-71-GB (EUCTR) | 25/09/201420140925 | 25/09/201420140925 | A study of treatment for polyarteritis nodosa in children | An Open Label Randomised Controlled Trial of Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission of Childhood Polyarteritis Nodosa - MYPAN An Open Label Randomised Controlled Trial of Mycophenolate Mofetil Versus Cyclophosphamide for the I ... | Childhood systemic polyarteritis nodosa (PAN) MedDRA version: 17.0;Level: LLT;Classification code 10036026;Term: Polyarteritis nodosa of childhood;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Childhood systemic polyarteritis nodosa (PAN) MedDRA version: 17.0;Level: LLT;Classification code 10 ... | Trade Name: CellCept Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: CellCept Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: CellCept (Mycophenolate Mofetil) Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: Cyclophosphamide Product Name: Cyclophosphamide Trade Name: CellCept Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate ... | University College London | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 3 | Croatia;Portugal;Slovenia;Greece;Spain;Turkey;United Kingdom;Italy;Czech Republic;Belgium;Poland;Germany;Netherlands;Sweden Croatia;Portugal;Slovenia;Greece;Spain;Turkey;United Kingdom;Italy;Czech Republic;Belgium;Poland;Ger ... | ||
| 4 | EUCTR2013-004668-71-BE (EUCTR) | 00000000 | 12/04/201720170412 | A study of treatment for polyarteritis nodosa in children | An Open Label Randomised Controlled Trial of Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission of Childhood Polyarteritis Nodosa - MYPAN An Open Label Randomised Controlled Trial of Mycophenolate Mofetil Versus Cyclophosphamide for the I ... | Childhood systemic polyarteritis nodosa (PAN) MedDRA version: 19.1;Level: LLT;Classification code 10036026;Term: Polyarteritis nodosa of childhood;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Childhood systemic polyarteritis nodosa (PAN) MedDRA version: 19.1;Level: LLT;Classification code 10 ... | Trade Name: CellCept Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: CellCept Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: CellCept (Mycophenolate Mofetil) Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: Cyclophosphamide Product Name: Cyclophosphamide INN or Proposed INN: CYCLOPHOSPHAMIDE INN or Proposed INN: CYCLOPHOSPHAMIDE Trade Name: CellCept Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate ... | University College London | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 3 | Portugal;Slovenia;Greece;Spain;Turkey;United Kingdom;Italy;Czech Republic;Belgium;Poland;Croatia;Germany;Netherlands;Sweden Portugal;Slovenia;Greece;Spain;Turkey;United Kingdom;Italy;Czech Republic;Belgium;Poland;Croatia;Ger ... | ||
| 5 | EUCTR2013-004668-71-PT (EUCTR) | 00000000 | 16/02/201620160216 | A study of treatment for polyarteritis nodosa in children | An Open Label Randomised Controlled Trial of Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission of Childhood Polyarteritis Nodosa - MYPAN An Open Label Randomised Controlled Trial of Mycophenolate Mofetil Versus Cyclophosphamide for the I ... | Childhood systemic polyarteritis nodosa (PAN) MedDRA version: 18.1;Level: LLT;Classification code 10036026;Term: Polyarteritis nodosa of childhood;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Childhood systemic polyarteritis nodosa (PAN) MedDRA version: 18.1;Level: LLT;Classification code 10 ... | Trade Name: CellCept Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: CellCept Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: CellCept (Mycophenolate Mofetil) Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: Cyclophosphamide Product Name: Cyclophosphamide INN or Proposed INN: CYCLOPHOSPHAMIDE Trade Name: CellCept Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate ... | University College London | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 3 | Portugal;Slovenia;Greece;Spain;Turkey;United Kingdom;Italy;Czech Republic;Belgium;Poland;Croatia;Germany;Netherlands;Sweden Portugal;Slovenia;Greece;Spain;Turkey;United Kingdom;Italy;Czech Republic;Belgium;Poland;Croatia;Ger ... |
43. Microscopic polyangiitis
Clinical trials : 88 / Drugs : 81 - (DrugBank : 21) / Drug target genes : 15 - Drug target pathways : 90
Showing 1 to 1 of 1 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00405860 (ClinicalTrials.gov) | December 200220021200 | 29/11/200620061129 | CellCept in p-ANCA Vasculitis | A Pilot Study of Mycophenolate Mofetil (MMF) in Patients With p-ANCA Microscopic Polyangiitis and Mild to Moderate Renal Dysfunction. A Pilot Study of Mycophenolate Mofetil (MMF) in Patients With p-ANCA Microscopic Polyangiitis and Mi ... | MPO-ANCA Vasculitis;Microscopic Polyangiitis | Drug: CellCept (mycophenolate mofetil) | Mayo Clinic | Roche Pharma AG | Completed | 18 Years | N/A | Both | 18 | Phase 1 | United States |